Cite
HARVARD Citation
Ramos Perez, J. et al. (2022). Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leukemia & lymphoma. 63 (3), pp. 672-675. [Online].